Image

Assessment of an Intensive Motor Telerehabilitation Program for Stroke Patients

Assessment of an Intensive Motor Telerehabilitation Program for Stroke Patients

Recruiting
18-85 years
All
Phase N/A

Powered by AI

Overview

Stroke is a major cause of motor disability, particularly hemiplegia, and its incidence is increasing as the population ages. Despite partial spontaneous recovery in the first three months, 80% of patients retain a motor deficit after six months, requiring intensive rehabilitation to maximize recovery. However, after hospitalization, access to intensive rehabilitation is limited, due to geographical and mobility constraints, and the lack of reimbursement for private occupational therapy.

Telerehabilitation, using digital technologies, can overcome these difficulties by offering interactive, accessible rehabilitation at home. Studies show that its effectiveness is comparable to that of clinical rehabilitation.

Our study therefore proposes to evaluate the feasibility and effects of a home-based telerehabilitation program using the MindMotion GO device (MindMaze). This 12-week program aims to provide an additional intensive dose of rehabilitation to the standard of care, with 300 minutes of weekly active therapy, planned and monitored remotely by a therapist.

Description

Stroke is a major cause of motor disability, particularly hemiplegia, and its incidence is increasing as the population ages. Despite partial spontaneous recovery in the first three months, 80% of patients retain a motor deficit after six months, requiring intensive rehabilitation to maximize recovery. However, after hospitalization, access to intensive rehabilitation is limited, due to geographical and mobility constraints, and the lack of reimbursement for private occupational therapy.

Telerehabilitation, using digital technologies, can overcome these difficulties by offering interactive, accessible rehabilitation at home. Studies show that its effectiveness is comparable to that of clinical rehabilitation.

Our study therefore proposes to evaluate the feasibility and effects of a home-based telerehabilitation program using the MindMotion GO device (MindMaze). This 12-week program aims to provide an additional intensive dose of rehabilitation to the standard of care, with 300 minutes of weekly active therapy, planned and monitored remotely by a therapist. It combines synchronous (1time a week with a therapist) and asynchronous (autonomous) sessions.

This program is integrated into the post-stroke care pathway by facilitating the transition from hospital to home, without prolonging hospitalization or increasing face-to-face sessions.

The study will be a single-center randomized controlled trial, targeting patients in the sub-acute and chronic stages of stroke.

Eligibility

Inclusion Criteria:

  • Hospitalized for a first ischemic or hemorrhagic stroke
  • Stroke occurrence more than 30 days prior
  • Presenting motor deficits affecting the upper limb, with or without involvement of the lower limb
  • Able to follow the instructions of the home program using the MindMotion GO device
  • Having at home an accessible email address, an Internet connection with password, a smartphone, a screen or TV with HDMI input (Full HD 1080p resolution), and a free space of approximately 1 m x 2.5 m in front of the screen
  • Ability to sit without assistance
  • Patient agreeing to participate in the study by signing an informed consent form
  • Affiliated with, or entitled to, a social security scheme

Exclusion Criteria:

History of stroke

  • Neurological pathology other than stroke
  • Patient with uncontrolled epilepsy or seizure disorder
  • Cardiac disease limiting exercise
  • Pain limiting rehabilitation dose
  • Major comprehension problems or severe psychiatric and/or cognitive disorders that could compromise understanding of the protocol and the smooth running of the study.
  • Uncorrected hearing or visual deficits
  • Severe apraxia
  • Severe memory impairment
  • Severe unilateral spatial neglect
  • Total plegia of affected limb
  • Pregnant, parturient or breast-feeding women
  • Persons deprived of their liberty by judicial or administrative decision
  • Persons admitted to a health or social institution for purposes other than research
  • Adults under legal protection (guardianship, curatorship)
  • Subjects participating in other intervention research.

Study details
    Stroke

NCT07254195

Hospices Civils de Lyon

13 May 2026

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.